BioArctic Neuroscience AB
– Develops new treatments for neurologic disorders
BioArctic Neuroscience AB
BioArctic Neuroscience is working with antibodies and proteins in neurologic disorders. The company was founded 2003 and has 30 employees in Stockholm. The company’s leading projects are presented on this page. BioArctic develops new treatments for neurodegenerative diseases. The R&D portfolio comprises several novel therapeutic projects in different stages of development.
BAN2401 is the company’s most advanced project directed towards stopping or modifying the disease progression in Alzheimer’s disease. Currently, there are no effective treatments that can stop the disease, which is a devastating neurodegenerative disease characterized by an insidious onset and progressive loss of memory and cognition. The disorder is also manifested by behavioural disturbances and functional impairment, and leads to premature death. Alzheimer’s disease is a demographic time bomb. The disease is age-related and the number of patients doubles every five years beyond age 65, meaning that 30% of 85-year-olds are suffering from the disease. Current estimates indicate 35.6% million people worldwide are living with dementia and researchers estimate that this number could triple by 2050. BAN2401 is a humanized monoclonal antibody selectively targeting the toxic Aß protofibrils, which are believed to be central for disease progression and toxicity in Alzheimer’s disease. BAN2401 is now in late clinical development as the company’s lead immunotherapeutic drug candidate developed with BioArctic’s technology. The antibody was discovered together with Rudbeck Laboratory, Uppsala University. In collaboration with Eisai and Biogene Idec a phase IIb clinical trial is ongoing in early Alzheimer patients in the US, Canada and EU including Sweden. In addition, early clinical development is ongoing in Japan.
Brain images provided by PET-Centre, Uppsala University Hospital showing a normal brain (left) and an Alzheimer brain (right)
Parkinson’s disease is the most common movement disorder. Current treatments for Parkinson’s disease are based on increasing the levels of dopamine in the brain. These drugs can’t stop the disease progression and do not affect all symptoms of the disease. Today, there is no drug approved for a related disorder -Dementia with Lewy bodies. Both these disorders are believed to be caused by aggregation of a common protein in brain, α-synuclein. BioArctic develops new treatments for these diseases. The target is soluble aggregates of α-synuclein, which is now believed to be the culprit of these disorders. BioArctic has developed antibodies that can remove or inactivate these toxic forms of α-synuclein. This treatment has the potential to halt the disease progression.
Image shows the laboratory at BioArctic
Complete Spinal Cord Injury
A growth factor and a medicinal device will in combination be used during neurosurgical procedures to recreate a functional spinal cord in subjects with a total loss of motor and sensory function in the legs. No treatment exists for these patients today. To promote nerve grafting procedures, a biodegradable device has been constructed where a growth factor is inserted together with peripheral nerves. The product is used during the neurosurgical procedure, when injured tissue is replaced, to connect viable nerves on each side of the injured segment. After the operation the patients will need intensive training in a robotic system. The project is built on innovative research from Karolinska Institutet, the Karolinska University Hospital and Ångström laboratory in Uppsala. The drug candidate received Orphan Drug Designation in EU 2010 and the US 2011. A clinical study is ongoing in Sweden and will also include other Nordic countries. The project has received funding from Vinnova and EU Horizon2020.
Image provided by Dr. Björn Hedman, Rehabstation Stockholm showing robotic training used for rehabilitation